Clinical Trial · NCT03384511

The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.

Overview

This is an open-label, single arm study to explore whether 18F-ALF-NOTA-PRGD2 PET/CT scan can predict the efficacy and adverse events of apatinib in patients with malignancies. Integrin αvβ3 has been shown to play an important role in angiogenesis and up-regulated obviously in various types of tumor cells and activated endothelial cells. The arginine-glycine-aspartic acid (RGD) tripeptide sequence can bind to integrin αvβ3 with high affinity and specificity. The 18F-ALF-NOTA-PRGD2 will highly combine with αvβ3, and thus will monitor the antiangiogenic status.In the current study, investigators propose to evaluate the feasibility of 18F-RGD PET/CT in monitoring efficacy and adverse events of apatinib in malignancies.

Sponsor

Peking University Cancer Hospital & Institute

Phase

Phase 4

Contacts

Shuanghu Yuan, MD;PhD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT03384511

Eligibility

Inclusion

Karnofsky performance status (KPS) ≥70
Measurable primary tumors according to Response Evaluation Criteria in Solid Tumors (RECIST)
Clinical diagnosis of malignancies
Scheduled for second- or third-line apatinib therapy

Exclusion

Active infection, myocardial infarction within 6 months, symptoms of heart disease, including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive therapy
Inability to complete the required examinations
The claustrophobic patients and patients with implanted metal objects